```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1617srh

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04   STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11   KOREAPAT updates resume
 NEWS  7  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  9  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 11  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 12  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 11   CHEMSAFE reloaded and enhanced
 NEWS 14  JUl 14   FSTA enhanced with Japanese patents
 NEWS 15  JUl 19   Coverage of Research Disclosure reinstated in DWPI
 NEWS 16  AUG 09   INSPEC enhanced with 1898-1968 archive

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:55:41 ON 16 AUG 2006

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21
```

```
FILE 'REGISTRY' ENTERED AT 19:55:53 ON 16 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 AUG 2006  HIGHEST RN 901654-60-2
DICTIONARY FILE UPDATES:  15 AUG 2006  HIGHEST RN 901654-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s chlorpheniramine
L1          25 CHLORPHENIRAMINE

=> s chlorpheniramine/cn
L2           1 CHLORPHENIRAMINE/CN

=> s brompheniramine/cn
L3           1 BROMPHENIRAMINE/CN

=> sel rn name l2
E1 THROUGH E19 ASSIGNED

=> sel rn name l3
E20 THROUGH E27 ASSIGNED

=> fil medl hcapl biosis uspatf wpids
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  15.96      16.17

FILE 'MEDLINE' ENTERED AT 19:56:57 ON 16 AUG 2006

FILE 'HCAPLUS' ENTERED AT 19:56:57 ON 16 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 19:56:57 ON 16 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 19:56:57 ON 16 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 19:56:57 ON 16 AUG 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s e1-19; s e20-27
   2 FILES SEARCHED...
```

```
   4 FILES SEARCHED...
L4        12508 ("Γ-(4-CHLOROPHENYL)-Γ-(2-PYRIDYL)PROPYLDIMETHYLAMIN
                E"/BI OR "(±)-CHLOROPHENIRAMINE"/BI OR "(±)-CHLORPHENIRAMI
               NE"/BI OR ALLERGICAN/BI OR CHLOROPHENAMINE/BI OR CHLOROPHENIRAMIN
               E/BI OR CHLOROPHENYLPYRIDAMINE/BI OR CHLOROPROPHENPYRIDAMINE/BI
               OR CHLORPHENAMINE/BI OR CHLORPHENIRAMINE/BI OR CHLORPROPHENPYRIDA
               MINE/BI OR "DL-1-(P-CHLOROPHENYL)-1-(2-PYRIDYL)-3-(DIMETHYLAMINO)
               PROPANE"/BI OR HAYNON/BI OR RS-CHLORPHENIRAMINE/BI OR "1-(P-CHLOR
               OPHENYL)-1-(2-PYRIDYL)-3-DIMETHYLAMINOPROPANE"/BI OR 132-22-9/BI
               OR "2-(P-CHLORO-A-(2-(DIMETHYLAMINO)ETHYL)BENZYL)PYRIDINE"/
               BI OR "3-(P-CHLOROPHENYL)-3-(2-PYRIDYL)-N,N-DIMETHYLPROPYLAMINE"/
               BI OR 4-CHLOROPHENIRAMINE/BI)

L5         2121 ("(±)-BROMPHENIRAMINE"/BI OR BROMPHENIRAMINE/BI OR PARABROMDY
                LAMINE/BI OR PARABROMODYLAMINE/BI OR "1-(P-BROMOPHENYL)-1-(2-PYR
               IDYL)-3-DIMETHYLAMINOPROPANE"/BI OR "2-(P-BROMO-A-(2-DIMETH
               YLAMINOETHYL)BENZYL)PYRIDINE"/BI OR "3-(P-BROMOPHENYL)-3-(2-PYRID
               YL)-N,N-DIMETHYLPROPYLAMINE"/BI OR 86-22-6/BI)

=> s motion sickness
L6         6180 MOTION SICKNESS

=> s l4 or l5
L7        13246 L4 OR L5

=> s l6 (l) l7
L8          176 L6 (L) L7

=> s l6 (s) l7
L9           47 L6 (S) L7

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10           45 DUP REM L9 (2 DUPLICATES REMOVED)

=> d ibib abs 44-45

L10  ANSWER 44 OF 45  USPATFULL on STN
ACCESSION NUMBER:         89:1121  USPATFULL
TITLE:                    Polymer blends having reverse phase morphology for
                          controlled delivery of bioactive agents
INVENTOR(S):              Kashdan, David S., Kingsport, TN, United States  37663
PATENT ASSIGNEE(S):       Eastman Kodak Company, Rochester, NY, United States
                          (U.S. corporation)

                               NUMBER        KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 4795641               19890103
APPLICATION INFO.:        US 1987-87566            19870820  (7)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             Granted
PRIMARY EXAMINER:         Dixon, Jr., William R.
ASSISTANT EXAMINER:       Brunsman, David M.
LEGAL REPRESENTATIVE:     Savitsky, Thomas R., Heath, Jr., William P.
NUMBER OF CLAIMS:         40
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT:               1081
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Disclosed are polymer blends containing a minor amount of cellulose
       acetate and a major amount of cellulose acetate phthalate, cellulose
       acetate trimellitate or cellulose acetate succinate. The blends have
```

reverse phase morphology, that is, the minor component forms a continuous phase. The blends are useful for zero-order controlled delivery of bioactive agents such as pharmaceutical and agricultural chemicals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 45 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:466685 HCAPLUS
DOCUMENT NUMBER: 109:66685
TITLE: Suncus murinus as a new experimental model for motion sickness
AUTHOR(S): Ueno, Shinya; Matsuki, Norio; Saito, Hiroshi
CORPORATE SOURCE: Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan
SOURCE: Life Sciences (1988), 43(5), 413-20
CODEN: LIFSAK; ISSN: 0024-3205
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The characteristics of motion sickness and the effects of possible prophylactic drugs were studied in S. murinus (house musk shrew) as a potential exptl. model for motion sickness. Mild reciprocal shaking (amplitude: 10-40 mm; frequency: 0.5-3.0 Hz) induced vomiting in most S. murinus within 2 min. Adaptation was observed when the motion stimulus was repeated with an interval of 2-3 days. During the repetitive motion training, both the number of sensitive animals and the number of vomiting episodes decreased, and the time from the start of shaking to the 1st vomiting was extended. S.c. injection of scopolamine (100 mg/kg), chlorpromazine (8 mg/kg), promethazine (50 mg/kg), diphenhydramine (20 mg/kg), chlorphenamine (20 mg/kg) and methamphetamine (2 mg/kg) decreased the emetic effect of motion sickness, but pyrilamine (20 mg/kg), meclizine (20 mg/kg) and dimenhydrinate (32 mg/kg) were not effective or were very weak. These results indicate that S. murinus is sensitive to motion stimulus and that antiemetic drugs are effective as prophylaxis. S. murinus Is useful as a new exptl. animal model for motion sickness.

=> d ibib abs 30-35

L10 ANSWER 30 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2002:205893 USPATFULL
TITLE: Over-coated product including consumable center and medicament
INVENTOR(S): Ream, Ronald L., Plano, IL, UNITED STATES
Matulewicz, Leonard, Oswego, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110581	A1	20020815
APPLICATION INFO.:	US 2002-44113	A1	20020109 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-631326, filed on 3 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000, PATENTED Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BELL, BOYD & LLOYD LLC, P. O. BOX 1135, CHICAGO, IL, 60690-1135
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 1160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a consumable center. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 31 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2002:148300 USPATFULL
TITLE: Flashmelt oral dosage formulation
INVENTOR(S): Kothari, Sanjeev, Princeton, NJ, UNITED STATES
Desai, Divyakant, West Windsor, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002076437	A1	20020620
APPLICATION INFO.:	US 2001-973226	A1	20011009 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-589340, filed on 7 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-547948, filed on 12 Apr 2000, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1888
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 32 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2002:188140 USPATFULL
TITLE: Over-coated product including tableted center and medicament
INVENTOR(S): Ream, Ronald L., Plano, IL, United States
Matulewicz, Leonard, Oswego, IL, United States
Wokas, William J., Bolingbrook, IL, United States
PATENT ASSIGNEE(S): Wm. Wrigley Jr. Company, Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6426090	B1	20020730
APPLICATION INFO.:	US 2001-955870		20010919 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-631326, filed on 3 Aug 2000 Continuation-in-part of Ser. No. US 2000-618808, filed on 18 Jul 2000 Continuation-in-part of Ser. No.

US 2000-510878, filed on 23 Feb 2000
Continuation-in-part of Ser. No. WO 1999-US29742, filed on 14 Dec 1999 Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Howard, S.
LEGAL REPRESENTATIVE: Bell, Boyd & Lloyd LLC
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 952
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted center. The tableted center is defined by compressible excipients. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 33 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2000:12451 USPATFULL
TITLE: Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
INVENTOR(S): Parab, Prakash, Williamsville, NY, United States
Yu, Cheng Der Tony, Amherst, NY, United States
Patel, Bhiku, Amherst, NY, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6019988		20000201	
APPLICATION INFO.:	US 1996-751293		19961118	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Clardy, S. Mark
ASSISTANT EXAMINER: Shelborne, Kathryne E.
LEGAL REPRESENTATIVE: Simon, Morton S., Zeller, Charles J.
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and means for enhancing the epidermal, transdermal and dermal permeation of a topically applied pharmacologically active agent (e.g., a drug or medicament) which has a low rate of skin penetration in the absence of a permeation enhancer and which is unstable and degrades during long-term storage with particular permeation enhancers. Also provided by the invention are methods and means to increase the skin penetration of a pharmacologically active agent which has a normally low rate of skin permeation and causes the instability and degradation of a permeation enhancer with which it is combined over a long period of time. Provided by the invention are at least one first composition containing a drug, a pharmaceutically acceptable salt, chemical derivative or formulation thereof, in a dermatologically acceptable vehicle, and at least one second composition

containing a permeation enhancer in an acceptable vehicle. The compositions are physically separated until application to a body or skin surface and are topically applied, either at the same time, or sequentially within a short time of each other, and mixed or blended to form a final active composition, preferably on the skin. In addition, a premixture of the compositions can be made and applied to the skin in accordance with the invention. The invention allows a therapeutically effective amount of drug to be delivered into the skin and systemic circulation and provides significant enhancement of a drug's otherwise low level of skin permeation by the action of permeation enhancer in the active composition at the point of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 34 OF 45 USPATFULL on STN

ACCESSION NUMBER:	1999:67030 USPATFULL
TITLE:	Prophylactic and therapeutic treatment of skin sensitization and irritation
INVENTOR(S):	Wille, John J., Trenton, NJ, United States Kydonieus, Agis, Kendall Park, NJ, United States
PATENT ASSIGNEE(S):	E.R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5912010		19990615
APPLICATION INFO.:	US 1997-897905		19970721 (8)

RELATED APPLN. INFO.:	Division of Ser. No. US 1995-545244, filed on 19 Oct 1995, now patented, Pat. No. US 5686100 which is a continuation-in-part of Ser. No. US 1994-343156, filed on 22 Nov 1994, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Brouillette, D. Gabrielle
LEGAL REPRESENTATIVE:	Kilcoyne, John M., Furman, Jr., Theodore R.
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
LINE COUNT:	906

AB Methods and devices for preventing and/or treating an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of a loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid.

L10 ANSWER 35 OF 45 USPATFULL on STN

ACCESSION NUMBER:	1998:150981 USPATFULL
TITLE:	Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
INVENTOR(S):	Wille, John J., Trenton, NJ, United States Kydonieus, Agis F., Kendall Park, NJ, United States
PATENT ASSIGNEE(S):	Bristol-Myers Squibb Company, Skillman, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843979		19981201
APPLICATION INFO.:	US 1996-598627		19960212 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-198003, filed on 17 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-22080, filed on 25 Feb 1993, now abandoned
DOCUMENT TYPE:	Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Kilcoyne, John M., Furman, Jr., Theodore R.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1565
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for inhibiting or preventing the skin irritating or sensitizing effects of a skin irritating or sensitizing component of a dermal or transdermal drug delivery system are disclosed. The composition comprises a mast cell degranulating agent which is capable of inducing a state of immunological tolerance to the skin sensitizing agent by delivery prior to, or at the onset of transdermal drug delivery. Such an agent, preferably cis-urocanic acid or an analogue or metabolite thereof, can be administered before, during or after each transdermal drug delivery to achieve immune tolerance countersensitization. Alternatively, the agent can be used to induce countersensitization. The agent is preferably capable of permeating the epidermis and is administered transdermally. Novel methods and compositions comprising cis-urocanic acid or an analogue or metabolite thereof to obtain anti-inflammatory effects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> focus
PROCESSING COMPLETED FOR L10
L11 45 FOCUS L10 1-

=> d ibib abs 1-10

L11 ANSWER 1 OF 45 MEDLINE on STN
ACCESSION NUMBER: 2004257434 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15156097
TITLE: Chlorpheniramine for motion sickness.
AUTHOR: Buckey Jay C; Alvarenga Donna; Cole Bernard; Rigas James R
CORPORATE SOURCE: Department of Medicine, Dartmouth Medical School, One Medical Center Dr., Lebanon, New Hampshire 03756, USA.. jay.buckey@dartmouth.edu
SOURCE: Journal of vestibular research : equilibrium & orientation, (2004) Vol. 14, No. 1, pp. 53-61.
Journal code: 9104163. ISSN: 0957-4271.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Space Life Sciences
ENTRY MONTH: 200412
ENTRY DATE: Entered STN: 25 May 2004
Last Updated on STN: 19 Dec 2004
Entered Medline: 7 Dec 2004
AB BACKGROUND: Motion sickness remains a significant problem for travelers and for those involved in naval, aviation and space operations. Many motion sickness remedies are also sedating, making them undesirable in many settings. METHODS: We studied chlorpheniramine as a potential motion sickness treatment. A placebo-controlled, double-blind, dose-ranging trial was performed to establish the most effective dose and the drug's effects on cognition. Eighteen normal, motion sickness susceptible subjects received placebo, low dose (4 mg) or high dose (12 mg)

chlorpheniramine 3.5 hours before off-axis vertical rotation. Cognitive testing included a battery of objective and subjective tests performed before drug ingestion, at peak drug effect and following rotation. RESULTS: Chlorpheniramine significantly increased the time in the chair compared to placebo at high dose (7.2 minutes to 11.7 minutes) and low dose (7.2 minutes to 10.2 minutes). Chlorpheniramine did not affect performance on objective cognitive tests. Subjects reported significantly more sleepiness and less alertness with high-dose chlorpheniramine, although they could not reliably determine when they had received active drug. CONCLUSION: Chlorpheniramine is effective and could be considered for use against motion sickness . Chlorpheniramine also has the potential to be administered transdermally.

L11 ANSWER 2 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:964840 HCAPLUS
DOCUMENT NUMBER: 141:388746
TITLE: Pheniramine for preventing or treating motion sickness
INVENTOR(S): Buckey, Jay C.; Brown, Larry R.; Alvarenga, Donna L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004225019	A1	20041111	US 2004-786429		20040225
PRIORITY APPLN. INFO.:			US 2003-450132P	P	20030225

AB The present invention provides a method of preventing or treating motion sickness by orally or topically administering a halogenated pheniramine.

L11 ANSWER 3 OF 45 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:466685 HCAPLUS
DOCUMENT NUMBER: 109:66685
TITLE: Suncus murinus as a new experimental model for motion sickness
AUTHOR(S): Ueno, Shinya; Matsuki, Norio; Saito, Hiroshi
CORPORATE SOURCE: Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan
SOURCE: Life Sciences (1988), 43(5), 413-20
CODEN: LIFSAK; ISSN: 0024-3205
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The characteristics of motion sickness and the effects of possible prophylactic drugs were studied in S. murinus (house musk shrew) as a potential exptl. model for motion sickness. Mild reciprocal shaking (amplitude: 10-40 mm; frequency: 0.5-3.0 Hz) induced vomiting in most S. murinus within 2 min. Adaptation was observed when the motion stimulus was repeated with an interval of 2-3 days. During the repetitive motion training, both the number of sensitive animals and the number of vomiting episodes decreased, and the time from the start of shaking to the 1st vomiting was extended. S.c. injection of scopolamine (100 mg/kg), chlorpromazine (8 mg/kg), promethazine (50 mg/kg), diphenhydramine (20 mg/kg), chlorphenamine (20 mg/kg) and methamphetamine (2 mg/kg) decreased the emetic effect of motion sickness, but pyrilamine (20 mg/kg), meclizine (20 mg/kg) and dimenhydrinate (32 mg/kg) were not effective or were very weak. These results indicate that S. murinus is sensitive to motion stimulus and that antiemetic drugs are effective as prophylaxis. S. murinus Is useful as a new exptl. animal model for motion sickness.

L11 ANSWER 4 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2005:170925 USPATFULL
TITLE: Tablets quickly disintegrating in mouth
INVENTOR(S): Ohmori, Shinji, Nishinomiya-shi, JAPAN
Ohno, Yasuo, Osaka-shi, JAPAN
Makino, Tadashi, Ibaraki-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005147672	A1	20050707
APPLICATION INFO.:	US 2005-35956	A1	20050118 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2003-395137, filed on 25 Mar 2003, PENDING Division of Ser. No. US 2001-869979, filed on 20 Aug 2001, ABANDONED A 371 of International Ser. No. WO 2000-JP4081, filed on 22 Jun 2000

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-183624	19990629

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021, US
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1-9
LINE COUNT: 499
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Tablets quickly disintegrating in the mouth which comprise a bitter drug ingredient and a bitterness-reducing ingredient composed of an essential oil, a high sweetness-sweetener and/or an acidic phospholipid or its lyso-derivative. When taken even without water, these tablets exhibit little bitterness. Thus, a bitter drug ingredient can be formulated without coating into tablets quickly disintegrating in the mouth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:231681 USPATFULL
TITLE: Tablets quickly disintegrating in mouth
INVENTOR(S): Ohmori, Shinji, Nishinomiya-shi, JAPAN
Ohno, Yasuo, Osaka-shi, JAPAN
Makino, Tadashi, Ibaraki-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003161879	A1	20030828
APPLICATION INFO.:	US 2003-395137	A1	20030325 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-869979, filed on 20 Aug 2001, PENDING A 371 of International Ser. No. WO 2000-JP4081, filed on 22 Jun 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-183624	19990629

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 502
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Tablets quickly disintegrating in the mouth which comprise a bitter drug

ingredient and a bitterness-reducing ingredient composed of an essential oil, a high sweetness-sweetener and/or an acidic phospholipid or its lyso-derivative. When taken even without water, these tablets exhibit little bitterness. Thus, a bitter drug ingredient can be formulated without coating into tablets quickly disintegrating in the mouth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:133515 USPATFULL
TITLE: PROCESS FOR MAKING PERSONAL CARE COMPOSITIONS COMPRISING TITANIUM DIOXIDE AND PERSONAL CARE COMPOSITIONS MADE BY THE PROCESS
INVENTOR(S): Stier, Roger E., Clifton, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003091600	A1	20030515	
	US 6569439	B2	20030527	
APPLICATION INFO.:	US 2001-10362	A1	20011113	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Norris, McLaughin & Marcus, P.O. Box 1018, Somerville, NJ, 08876-1018
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns a process for making personal care compositions and opacifying agents, and corresponding products, having a stable cloudy and milky appearance. The components are processed in a specific sequence in which titanium dioxide is added after thickening agent which comprises a hydrophilic colloid. The composition may, optionally, comprise calcium lactate, calcium lactate salts and combinations thereof. The products, and process, may also comprise the addition of other components such as filler, additives, colorants, cooling agents, warming agents, numbing agents, additional flavorings, active compounds, pharmaceutical actives and excipients or finished bases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 45 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-399399 [37] WPIDS
CROSS REFERENCE: 2003-067940 [06]; 2003-067941 [06]; 2003-067942 [06]; 2003-067943 [06]; 2003-067944 [06]; 2003-067945 [06]; 2003-067946 [06]; 2003-067947 [06]; 2003-067948 [06]; 2003-067949 [06]; 2003-067950 [06]; 2003-067951 [06]; 2003-067952 [06]; 2003-067953 [06]; 2003-067954 [06]; 2003-067955 [06]; 2003-067956 [06]; 2003-067957 [06]; 2003-112259 [10]; 2003-120749 [11]; 2003-120750 [11]; 2003-129366 [12]; 2003-140547 [13]; 2003-156819 [15]; 2003-371875 [35]; 2003-402067 [38]; 2003-457351 [43]; 2003-505170 [47]; 2003-569111 [53]; 2003-597221 [56]; 2003-598318 [56]; 2004-089096 [09]; 2004-389125 [36]; 2004-641994 [62]; 2004-642029 [62]
DOC. NO. NON-CPI: N2004-318404
TITLE: Composition useful for delivery of drug comprises condensation aerosol formed by volatilization of heat stable drug composition to produce a heated vapor and condensing the heated vapor to form condensation aerosol particles.
DERWENT CLASS: B07 P34
INVENTOR(S): HALE, R L; HODGES, C C; LLOYD, P M; LU, A T; MYERS, D J;

RABINOWITZ, J D; WENSLEY, M J
PATENT ASSIGNEE(S): (ALEX-N) ALEXZA MOLECULAR DELIVERY CORP
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2004099269	A1	20040527	(200437)*		84

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
US 2004099269	A1	Provisional	US 2001-294203P	20010524
		Provisional	US 2001-296225P	20010605
		Provisional	US 2001-317479P	20010905
		CIP of	US 2001-57197	20011026
		CIP of	US 2001-57198	20011026
		Provisional	US 2001-335049P	20011030
		Provisional	US 2001-336218P	20011030
		Provisional	US 2001-345145P	20011109
		Provisional	US 2001-345876P	20011109
		Provisional	US 2001-345882P	20011109
		Provisional	US 2001-332165P	20011121
		Provisional	US 2001-332279P	20011121
		Provisional	US 2001-332280P	20011121
		Provisional	US 2001-342066P	20011218
		CIP of	US 2002-50056	20020114
		Provisional	US 2002-371457P	20020409
		CIP of	US 2002-146080	20020513
		CIP of	US 2002-146086	20020513
		CIP of	US 2002-146088	20020513
		CIP of	US 2002-146515	20020513
		CIP of	US 2002-146516	20020513
		CIP of	US 2002-150267	20020515
		CIP of	US 2002-150268	20020515
		CIP of	US 2002-151596	20020516
		CIP of	US 2002-151626	20020516
		CIP of	US 2002-150591	20020517
		CIP of	US 2002-150857	20020517
		CIP of	US 2002-152639	20020520
		CIP of	US 2002-152640	20020520
		CIP of	US 2002-152652	20020520
		CIP of	US 2002-153139	20020520
		CIP of	US 2002-153311	20020521
		CIP of	US 2002-153313	20020521
		CIP of	US 2002-153831	20020521
		CIP of	US 2002-153839	20020521
		CIP of	US 2002-155373	20020522
		CIP of	US 2002-155621	20020522
		CIP of	US 2002-155703	20020522
		CIP of	US 2002-155705	20020522
		CIP of	US 2002-154594	20020523
		CIP of	US 2002-154765	20020523
		CIP of	US 2002-155097	20020523
		Provisional	US 2002-412068P	20020918
		CIP of	US 2002-280315	20021025
		CIP of	US 2002-302010	20021121
		CIP of	US 2002-302614	20021121
		CIP of	US 2002-322227	20021217
		CIP of	US 2003-633876	20030804
		CIP of	US 2003-633877	20030804
			US 2003-718982	20031120

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 2004099269	A1 CIP of	US 6682716
	CIP of	US 6716415
	CIP of	US 6716416
	CIP of	US 6716417

PRIORITY APPLN. INFO: US 2003-718982 20031120; US
2001-294203P 20010524; US
2001-296225P 20010605; US
2001-317479P 20010905; US
2001-57197 20011026; US
2001-57198 20011026; US
2001-335049P 20011030; US
2001-336218P 20011030; US
2001-345145P 20011109; US
2001-345876P 20011109; US
2001-345882P 20011109; US
2001-332165P 20011121; US
2001-332279P 20011121; US
2001-332280P 20011121; US
2001-342066P 20011218; US
2002-50056 20020114; US
2002-371457P 20020409; US
2002-146080 20020513; US
2002-146086 20020513; US
2002-146088 20020513; US
2002-146515 20020513; US
2002-146516 20020513; US
2002-150267 20020515; US
2002-150268 20020515; US
2002-151596 20020516; US
2002-151626 20020516; US
2002-150591 20020517; US
2002-150857 20020517; US
2002-152639 20020520; US
2002-152640 20020520; US
2002-152652 20020520; US
2002-153139 20020520; US
2002-153311 20020521; US
2002-153313 20020521; US
2002-153831 20020521; US
2002-153839 20020521; US
2002-155373 20020522; US
2002-155621 20020522; US
2002-155703 20020522; US
2002-155705 20020522; US
2002-154594 20020523; US
2002-154765 20020523; US
2002-155097 20020523; US
2002-412068P 20020918; US
2002-280315 20021025; US
2002-302010 20021121; US
2002-302614 20021121; US
2002-322227 20021217; US
2003-633876 20030804; US
2003-633877 20030804

AN 2004-399399 [37] WPIDS
CR 2003-067940 [06]; 2003-067941 [06]; 2003-067942 [06]; 2003-067943 [06];
2003-067944 [06]; 2003-067945 [06]; 2003-067946 [06]; 2003-067947 [06];

2003-067948 [06]; 2003-067949 [06]; 2003-067950 [06]; 2003-067951 [06]; 2003-067952 [06]; 2003-067953 [06]; 2003-067954 [06]; 2003-067955 [06]; 2003-067956 [06]; 2003-067957 [06]; 2003-112259 [10]; 2003-120749 [11]; 2003-120750 [11]; 2003-129366 [12]; 2003-140547 [13]; 2003-156819 [15]; 2003-371875 [35]; 2003-402067 [38]; 2003-457351 [43]; 2003-505170 [47]; 2003-569111 [53]; 2003-597221 [56]; 2003-598318 [56]; 2004-089096 [09]; 2004-389125 [36]; 2004-641994 [62]; 2004-642029 [62]

AB US2004099269 A UPAB: 20041001

NOVELTY - A composition comprises a condensation aerosol formed by volatilization of a heat stable drug composition to produce a heated vapor of the drug composition and condensing the heated vapor of the drug composition to form condensation aerosol particles which contain less than 10% drug degradation products and has MMAD less than 3 micro m.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a kit for delivering a drug condensation aerosol comprising a composition devoid of solvents and excipients comprising a heat stable drug compound in a unit dose form and a device for forming or dispensing a drug aerosol comprising an element configured to heat the composition to form a vapor, an element allowing the vapor to condense to form a condensation aerosol, and an element permitting a user to inhale the condensation aerosol.

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - For delivery of a drug; inhalation therapy (claimed); for the treatment of disease and intermittent or acute conditions.

ADVANTAGE - The aerosol is devoid of excipient or devoid of propellants and organic solvents. The drug exhibits an increasing level of drug degradation products with increasing film thickness. The condensation aerosol particles has less than 10 (preferably less than 5, especially less than 2.5)% drug degradation products and has aerosol mass median aerodynamic diameter (MMAD) of less than 3 (preferably 1 - 3, especially 0.01 - 3, particularly less than 1) mu . The drug aerosol has a purity of 90 - 99.8 (preferably 93 - 99.7, especially 95 - 99.5, particularly 96.5 - 99.2).

Dwg.0/27

L11 ANSWER 8 OF 45 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1990:303605 BIOSIS

DOCUMENT NUMBER: PREV199039021786; BR39:21786

TITLE: EFFECTS OF VARIOUS TYPES OF ANTIHISTAMINES AND INHIBITORS OF HISTAMINE RELEASE ON MOTION-INDUCED EMESIS OF SUNCUS-MURINUS.

AUTHOR(S): KAJI T [Reprint author]; MATSUKI N; SAITO H

CORPORATE SOURCE: DEP CHEM PHARMACOL, FAC PHARMACEUTICAL SCI, UNIV TOKYO, TOKYO 113, JPN

SOURCE: Japanese Journal of Pharmacology, (1990) Vol. 52, No. SUPPL. 1, pp. 194P.
Meeting Info.: 63RD ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY, TOKYO, JAPAN, MARCH 25-28, 1990.
JPN J PHARMACOL.
CODEN: JJPAAZ. ISSN: 0021-5198.

DOCUMENT TYPE: Conference; (Meeting)

FILE SEGMENT: BR

LANGUAGE: ENGLISH

ENTRY DATE: Entered STN: 27 Jun 1990
Last Updated on STN: 7 Aug 1990

L11 ANSWER 9 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:166503 USPATFULL

TITLE: Over-coated product including consumable center and medicament

INVENTOR(S): Ream, Ronald L., Plano, IL, UNITED STATES
Matulewicz, Leonard, Oswego, IL, UNITED STATES
Wokas, William J., Bollingbrook, IL, UNITED STATES

Ream, Brian, Plano, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006141008	A1	20060629
APPLICATION INFO.:	US 2005-269980	A1	20051109 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-44113, filed on 9 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2000-631326, filed on 3 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355265 Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BELL, BOYD & LLOYD LLC, P. O. BOX 1135, CHICAGO, IL, 60690-1135, US
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1361
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes one or more coatings having a medicament or agent. The coatings can further comprise one or more fat-based confectioneries to provide a coated product that has an improved aesthetic and taste appeal to a consumer. The medicament or agent is present within a coating that surrounds a consumable center. By chewing the coated product, the medicament or agent is released from the product within the buccal cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2006:143579 USPATFULL
TITLE: Tableted products including active agent
INVENTOR(S): Ream, Ronald L., Plano, IL, UNITED STATES
Matulewicz, Leonard, Oswego, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006121093	A1	20060608
APPLICATION INFO.:	US 2005-273942	A1	20051115 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-44113, filed on 9 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2000-631326, filed on 3 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355265 Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BELL, BOYD & LLOYD LLC, P. O. BOX 1135, CHICAGO, IL, 60690-1135, US
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1294
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the products.

The products include a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a consumable center. By chewing the products, the medicament or agent is released from the product within the buccal cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 11-19

L11 ANSWER 11 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2006:143578 USPATFULL
TITLE: Methods of producing coated products including active agent and products regarding same
INVENTOR(S): Ream, Ronald L., Plano, IL, UNITED STATES
Matulewicz, Leonard, Oswego, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006121092	A1	20060608
APPLICATION INFO.:	US 2005-273941	A1	20051115 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-44113, filed on 9 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2000-631326, filed on 3 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355265 Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BELL, BOYD & LLOYD LLC, P. O. BOX 1135, CHICAGO, IL, 60690-1135, US
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the products. The products include a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a consumable center. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2005:323888 USPATFULL
TITLE: Phytases, nucleic acids encoding them and methods of making and using them
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
Kretz, Keith A., San Marcos, CA, UNITED STATES
Gray, Kevin A., San Diego, CA, UNITED STATES
Barton, Nelson Robert, San Diego, CA, UNITED STATES
Garrett, James B., San Diego, CA, UNITED STATES
O'Donoghue, Eileen, San Diego, CA, UNITED STATES
Baum, William, La Jolla, CA, UNITED STATES
Robertson, Dan E., San Diego, CA, UNITED STATES
Zorner, Paul, Encinitas, CA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2005281792 A1 20051222
APPLICATION INFO.: US 2004-933115 A1 20040901 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-866379, filed on 24 May 2001, GRANTED, Pat. No. US 6855365 Continuation-in-part of Ser. No. US 2000-580515, filed on 25 May 2000, GRANTED, Pat. No. US 6720014 Continuation-in-part of Ser. No. US 1999-318528, filed on 25 May 1999, GRANTED, Pat. No. US 6183740 Continuation-in-part of Ser. No. US 1999-291931, filed on 13 Apr 1999, GRANTED, Pat. No. US 6190897 Continuation of Ser. No. US 1999-259214, filed on 1 Mar 1999, GRANTED, Pat. No. US 6110719 Division of Ser. No. US 1997-910798, filed on 13 Aug 1997, GRANTED, Pat. No. US 5876997
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DIVERSA C/O MOFO S.D., 3811 VALLEY CENTER DRIVE, SUITE 500, SAN DIEGO, CA, 92130, US
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 6758
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In one aspect, the invention provides a purified and modified phytase enzyme from Escherichia coli K12 appA phytase. The enzyme has phytase activity and improved thermal tolerance as compared with the wild-type enzyme. In addition, the enzyme has improved protease stability at low pH. Glycosylation of the modified phytase provided a further improved enzyme having improved thermal tolerance and protease stability. The enzyme can be produced from native or recombinant host cells and can be used to aid in the digestion of phytate where desired. In one aspect, the phytase of the present invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2005:282818 USPATFULL
TITLE: Phytases, nucleic acids encoding them and methods for making and using them
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
Kretz, Keith, San Marcos, CA, UNITED STATES
Gray, Kevin A., San Diego, CA, UNITED STATES
Barton, Nelson R., San Diego, CA, UNITED STATES
Garrett, James B., San Diego, CA, UNITED STATES
O'Donoghue, Eileen, San Diego, CA, UNITED STATES
Mathur, Eric J., Carlsbad, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005246780	A1	20051103
APPLICATION INFO.:	US 2005-56354	A1	20050211 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-156660, filed on 24 May 2002, PENDING Continuation-in-part of Ser. No. US 2001-866379, filed on 24 May 2001, GRANTED, Pat. No. US 6855365 Continuation-in-part of Ser. No. US 2000-580515, filed on 25 May 2000, GRANTED, Pat. No. US 6720014 Continuation-in-part of Ser. No. US 1999-318528, filed on 25 May 1999, GRANTED, Pat. No. US 6183740 Continuation-in-part of Ser. No. US 1999-291931, filed on 13 Apr 1999, GRANTED, Pat. No. US 6190897 Continuation of Ser. No. US 1999-259214, filed on 1 Mar 1999, GRANTED, Pat. No. US 6110719 Division of

Ser. No. US 1997-910798, filed on 13 Aug 1997, GRANTED, Pat. No. US 5876997
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DIVERSA C/O MOFO S.D., 3811 VALLEY CENTER DRIVE, SUITE 500, SAN DIEGO, CA, 92130, US
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 8612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated and recombinant phytase enzymes. In one aspect, the phytases are produced by modification of the wild type appA of E. coli. The enzyme can be produced from recombinant host cells. The phytases of the invention can be used to aid in the digestion of phytate where desired. In particular, the phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be thermotolerant and/or thermostable. Also provided are methods for obtaining a variant polynucleotide encoding a phytase and for obtaining a phytase with thermostability or thermotolerant at high or low temperatures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2005:243019 USPATFULL
TITLE: Nutraceuticals or nutritional supplements and method of making
INVENTOR(S): McGrew, Gordon N., Evanston, IL, UNITED STATES
Barkalow, David G., Deerfield, IL, UNITED STATES
Johnson, Sonya S., LaGrange Highlands, IL, UNITED STATES
Record, David W., River Forest, IL, UNITED STATES
Patel, Mansukh M., Downers Grove, IL, UNITED STATES
Nimz, Jack D., Wauconda, IL, UNITED STATES
Zibell, Steven E., Tinley Park, IL, UNITED STATES
Yatka, Robert J., Orland Park, IL, UNITED STATES
Greenberg, Michael J., Northbrook, IL, UNITED STATES
Aumann, Rebecca A., Chicago, IL, UNITED STATES
Zyck, Daniel J., North Riverside, IL, UNITED STATES
Sitler, Daniel J., Woodridge, IL, UNITED STATES
Hook, Jeffrey S., Lockport, IL, UNITED STATES
Maxwell, James R., Chicago, IL, UNITED STATES
Reed, Michael A., Merrillville, IN, UNITED STATES
Gudas, Victor V., Oak Lawn, IL, UNITED STATES
Schnell, Philip G., Downers Grove, IL, UNITED STATES
Tyrpin, Henry T., Palos Park, IL, UNITED STATES
Russell, Michael P., Evergreen Park, IL, UNITED STATES
Witkewitz, David L., Bridgeview, IL, UNITED STATES
Song, Joo H., Chicago, IL, UNITED STATES
Townsend, Donald J., Moores Hill, IN, UNITED STATES
Seielstad, Donald A., Frankfurt, IL, UNITED STATES
Ream, Ronald L., Plano, IL, UNITED STATES
Corriveau, Christine L., Orland Park, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES
Tongue, Thomas M., Joliet, IL, UNITED STATES
PATENT ASSIGNEE(S): Wm. Wrigley Jr. Company, Chicago, IL, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6949264	B1	20050927	
APPLICATION INFO.:	US 2000-621780		20000721	(9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1999-US29792, filed on 14 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-389211, filed on 2 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999, PENDING Continuation-in-part of Ser. No. US 308972, Pat. No. US 6165516 A 371 of International Ser. No. WO 1996-US18977, filed on 27 Nov 1996

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112389P	19981215 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Corbin, Arthur L
LEGAL REPRESENTATIVE: Shurtz, Steven P., Brinks Hofer Gilson & Lione
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3957
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for producing a chewing gum with a controlled release active agent, as well as the chewing gum so produced, is obtained by physically modifying the release properties of the active agent, such as a nutraceutical or nutritional supplement, by coating and drying. The active agent is coated by encapsulation, partially coated by agglomeration, entrapped by absorption, or treated by multiple steps of encapsulation, agglomeration, and absorption. The coated active agent is preferably then co-dried and particle sized to produce a release-modified active agent for use in chewing gum. The active agent may also be used in a coating on a chewing gum product, as part of a rolling compound applied to the chewing gum product, or as a part of the liquid in a liquid-center chewing gum product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2005:22856 USPATFULL
TITLE: Flashmelt oral dosage formulation
INVENTOR(S): Kotharl, Sanjeev, Princeton, NJ, UNITED STATES
Desal, Divyakant, West Windsor, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005019398	A1	20050127
APPLICATION INFO.:	US 2004-920851	A1	20040818 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-973226, filed on 9 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2000-589340, filed on 7 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-547948, filed on 12 Apr 2000, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: CLM-01-48
LINE COUNT: 1673
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients

such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2004:154383 USPATFULL
TITLE: Method for tissue perfusion
INVENTOR(S): Pietronigro, Dennis, Katonah, NY, United States
Decrescito, Vincent, Malverne Park, NY, United States
Kronenthal, Richard, Fairlawn, NJ, United States
McBeth, Dean, Croton-On-Hudson, NY, United States
PATENT ASSIGNEE(S): Direct Therapeutics, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6753005	B1	20040622
APPLICATION INFO.:	US 1999-458541		19991210 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-224599, filed on 31 Dec 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-70175P	19971231 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Darby & Darby
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 881
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are compositions and methods for the facile perfusion of a tissue with active agents following direct intra-tissue injection. Targets may consist of cells, cellular components, and/or extracellular components. The high perfusion efficiency permits high concentrations of active agents to be delivered to tissue targets resulting in high degrees of efficacy and in some instances the production of novel pharmacological activities of an active agent previously unknown or previously unattainable in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2004:120558 USPATFULL
TITLE: Recombinant phytases and methods of making and using them
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
Kretz, Keith, San Marcos, CA, UNITED STATES
Gray, Kevin A., San Diego, CA, UNITED STATES
Barton, Nelson R., San Diego, CA, UNITED STATES
Garrett, James B., San Diego, CA, UNITED STATES
O'Donoghue, Eileen, San Diego, CA, UNITED STATES
Mather, Eric J., Carlsbad, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004091968	A1	20040513

APPLICATION INFO.: US 2003-601319 A1 20030620 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-866379, filed on 24 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-580515, filed on 25 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-318528, filed on 25 May 1999, GRANTED, Pat. No. US 6183740 Continuation-in-part of Ser. No. US 1999-291931, filed on 13 Apr 1999, GRANTED, Pat. No. US 6190897 Continuation of Ser. No. US 1999-259214, filed on 1 Mar 1999, GRANTED, Pat. No. US 6110719 Division of Ser. No. US 1997-910798, filed on 13 Aug 1997, GRANTED, Pat. No. US 5876997
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON, PC, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130-2081
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 6026
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A purified and modified phytase enzyme from Escherichia coli K12 appA phytase is provided. The enzyme has phytase activity and improved thermal tolerance as compared with the wild-type enzyme. In addition, the enzyme has improved protease stability at low pH. Glycosylation of the modified phytase provided a further improved enzyme having improved thermal tolerance and protease stability. The enzyme can be produced from native or recombinant host cells and can be used to aid in the digestion of phytate where desired. In particular, the phytase of the present invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2004:90585 USPATFULL
TITLE: Phytase-containing foodstuffs and methods of making and using them
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, United States
Kretz, Keith A., San Marcos, CA, United States
PATENT ASSIGNEE(S): Diversa Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6720014	B1	20040413
APPLICATION INFO.:	US 2000-580515		20000525 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-318528, filed on 25 May 1999, now patented, Pat. No. US 6183740 Continuation-in-part of Ser. No. US 1999-291931, filed on 13 Apr 1999, now patented, Pat. No. US 6190897 Continuation of Ser. No. US 1999-259214, filed on 1 Mar 1999, now patented, Pat. No. US 6110719 Division of Ser. No. US 1997-910798, filed on 13 Aug 1997, now patented, Pat. No. US 5876997
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Ramirez, Delia
LEGAL REPRESENTATIVE: Fish & Richardson P.C.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 4885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A purified recombinant phytase enzyme derived from Escherichia coli B. The enzyme has a molecular light of about 47.1 kilodaltons and has phytase activity. The enzyme can be produced from native or recombinant host cells and can be used to aid in the digestion of phytate where desired. In particular, the phytase of the present invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2004:38236 USPATFULL
TITLE: Method for preparation of chewing gum with customer acceptable taste
INVENTOR(S): Andersen, Carsten, Vejle, DENMARK

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004028772	A1	20040212	
APPLICATION INFO.:	US 2003-344706	A1	20030804	(10)
	WO 2001-DK539		20010814	

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-1209	20000814

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 1742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for preparing a chewing gum with a customer acceptable taste of an active ingredient substantially during all chewing phases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 20-29

L11 ANSWER 20 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:337304 USPATFULL
TITLE: Prophylactic and therapeutic treatment of skin sensitization and irritation
INVENTOR(S): Wille, John J., Trenton, NJ, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6670395	B1	20031230	
APPLICATION INFO.:	US 1997-954946		19971022	(8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-670201, filed on 21 Jun 1996, now patented, Pat. No. US 5716987
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Kilcoyne, John K.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods, compositions and systems for preventing an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of phenoxyacetic acid and/or a lower alkyl ester thereof to a warm blooded animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:329830 USPATFULL
TITLE: Recombinant bacterial phytases and uses thereof
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
Kretz, Keith, San Marcos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232041	A1	20031218
APPLICATION INFO.:	US 2003-430356	A1	20030505 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-580515, filed on 25 May 2000, PENDING Division of Ser. No. US 2001-34985, filed on 21 Dec 2001, PENDING Continuation-in-part of Ser. No. US 1999-318528, filed on 25 May 1999, GRANTED, Pat. No. US 6183740 Continuation-in-part of Ser. No. US 1999-291931, filed on 13 Apr 1999, GRANTED, Pat. No. US 6190897 Continuation of Ser. No. US 1999-259214, filed on 1 Mar 1999, GRANTED, Pat. No. US 6110719 Division of Ser. No. US 1997-910798, filed on 13 Aug 1997, GRANTED, Pat. No. US 5876997
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON, PC, 4350 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO, CA, 92122
NUMBER OF CLAIMS: 94
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5153
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A purified recombinant phytase enzyme derived from Escherichia coli B. The enzyme has a molecular weight of about 47.1 kilodaltons and has phytase activity. The enzyme can be produced from native or recombinant host cells and can be used to aid in the digestion of phytate where desired. In particular, the phytase of the present invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:260570 USPATFULL
TITLE: Method of producing active agent coated chewing gum products
INVENTOR(S): Johnson, Sonya S., LaGrange Highlands, IL, United States
Record, David W., River Forest, IL, United States
Greenberg, Michael J., Northbrook, IL, United States
Reed, Michael A., Merrillville, IN, United States
Gudas, Victor V., Oak Lawn, IL, United States
Schnell, Philip G., Downers Grove, IL, United States
Seielstad, Donald A., Frankfurt, IL, United States
Tyrpin, Henry T., Palos Park, IL, United States
Russell, Michael P., Evergreen Park, IL, United States
Witkewitz, David L., Bridgeview, IL, United States

Song, Joo H., Chicago, IL, United States
Townsend, Donald J., Moores Hill, IN, United States
Yatka, Robert J., Orland Park, IL, United States
Ream, Ronald L., Plano, IL, United States
Corriveau, Christine L., Orland Park, IL, United States
Wokas, William J., Bolingbrook, IL, United States
PATENT ASSIGNEE(S): Wm. Wrigley Jr. Company, Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6627234	B1	20030930
APPLICATION INFO.:	US 2000-621643		20000721 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1999-US29742, filed on 14 Dec 1999 Continuation-in-part of Ser. No. US 1999-389211, filed on 2 Sep 1999, now abandoned Continuation-in-part of Ser. No. US 308972, now patented, Pat. No. US 6165516 Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Corbin, Arthur L.
LEGAL REPRESENTATIVE: Shurtz, Steven P., Brinks Hofer Gilson & Lione
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for producing a chewing gum with an improved release of active agent, as well as the chewing gum so produced, is obtained by adding an active agent to a chewing gum coating. The active agent is added to the coating in a coating solution or premixed with a flavor or solvent. The coating solution may contain sweetener or other transdermal enhancing agents to obtain increased transmucosal absorption. An active agent may also be used in the gum core.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:257364 USPATFULL
TITLE: Method of controlling release of bitterness inhibitors in chewing gum and gum produced thereby
INVENTOR(S): Gudas, Victor V., Oak Lawn, IL, UNITED STATES
Reed, Michael A., Merrillville, IN, UNITED STATES
Schnell, Philip G., Downers Grove, IL, UNITED STATES
Tyrpin, Henry T., Palos Park, IL, UNITED STATES
Witkewitz, David L., Bridgeview, IL, UNITED STATES
Greenberg, Michael J., Northbrook, IL, UNITED STATES
Wolf, Fred R., West Des Moines, IA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003180414	A1	20030925
APPLICATION INFO.:	US 2002-280688	A1	20021025 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-319054, filed on 26 May 1999, GRANTED, Pat. No. US 6472000 A 371 of International Ser. No. WO 1996-US20252, filed on 23 Dec 1996, PENDING Continuation-in-part of Ser. No. US 2000-621780, filed on 21 Jul 2000, PENDING Continuation of Ser. No. WO 1999-US29792, filed on 14 Dec 1999, PENDING

NUMBER	DATE

PRIORITY INFORMATION:	WO 1996-US18977	19961127
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BRINKS HOFER GILSON & LIONE, P.O. BOX 10395, CHICAGO, IL, 60610	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1395	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for producing a chewing gum with a controlled release of a bitterness inhibitor, as well as the chewing gum so produced, is obtained by physically modifying the release properties of the bitterness inhibitor by coating and drying. The bitterness inhibitor is coated by encapsulation, partially coated by agglomeration, entrapped by absorption, or treated by multiple steps of encapsulation, agglomeration, and absorption. The coated bitterness inhibitor is preferably then co-dried and particle sized to produce a release-modified bitterness inhibitor for use in chewing gum. When incorporated into the chewing gum, these particles are adapted to produce a fast release or a delayed release when the gum is chewed. The preferred bitterness inhibitor is sodium gluconate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 45 USPATFULL on STN

ACCESSION NUMBER:	2003:176198 USPATFULL		
TITLE:	Process for controlling release of active agents from a chewing gum coating and product thereof		
INVENTOR(S):	Song, Joo H., Chicago, IL, United States Townsend, Donald J., Moores Hill, IN, United States Record, David W., River Forest, IL, United States Tyrpin, Henry T., Palos Park, IL, United States Russell, Michael P., Evergreen Park, IL, United States Schnell, Philip G., Downers Grove, IL, United States Ream, Ronald L., Plano, IL, United States Corriveau, Christine L., Orland Park, IL, United States		
PATENT ASSIGNEE(S):	Wm. Wrigley Jr. Company, Chicago, IL, United States (U.S. corporation)		

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6586023	B1	20030701
APPLICATION INFO.:	US 2000-552290		20000419 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-389211, filed on 2 Sep 1999, now abandoned Continuation-in-part of Ser. No. US 308972		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112389P	19981215 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Corbin, Arthur L.
LEGAL REPRESENTATIVE:	Shurtz, Steven P., Brinks Hofer Gilson & Lione
NUMBER OF CLAIMS:	34
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT:	1694

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for producing a coated chewing gum with a controlled release of an active agent, as well as the chewing gum so produced, is obtained by physically modifying an active agent's properties by coating and drying.

An active agent is coated by encapsulation, partially coated by agglomeration, entrapped by absorption, or treated by multiple steps of encapsulation, agglomeration, and absorption. The coated active agent is then co-dried and particle sized to produce a release-modified active agent. When incorporated into a chewing gum coating, these particles release into the mouth but mask bitter and other off-tastes in the mouth, and are readily ingested.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2003:152292 USPATFULL

TITLE: Phytases, nucleic acids encoding them and methods for making and using them

INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
Kretz, Keith, San Marcos, CA, UNITED STATES
Gray, Kevin A., San Diego, CA, UNITED STATES
Barton, Nelson R., San Diego, CA, UNITED STATES
Garrett, James B., Poway, CA, UNITED STATES
O'Donoghue, Eileen, San Diego, CA, UNITED STATES
Mathur, Eric J., Carlsbad, CA, UNITED STATES

PATENT ASSIGNEE(S): Diversa Corporation, San Diego, CA, UNITED STATES, 92121 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003103958	A1	20030605
	US 7078035	B2	20060718
APPLICATION INFO.:	US 2002-156660	A1	20020524 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-866379, filed on 24 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-580515, filed on 25 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-318528, filed on 25 May 1999, GRANTED, Pat. No. US 6183740 Continuation-in-part of Ser. No. US 1999-291931, filed on 13 Apr 1999, GRANTED, Pat. No. US 6190897 Continuation of Ser. No. US 1999-259214, filed on 1 Mar 1999, GRANTED, Pat. No. US 6110719 Division of Ser. No. US 1997-910798, filed on 13 Aug 1997, GRANTED, Pat. No. US 5876997

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FISH & RICHARDSON, PC, 4350 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO, CA, 92122

NUMBER OF CLAIMS: 206

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 22 Drawing Page(s)

LINE COUNT: 9531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated and recombinant phytase enzymes. In one aspect, the phytases are produced by modification of the wild type appA of E. coli. The enzyme can be produced from recombinant host cells. The phytases of the invention can be used to aid in the digestion of phytate where desired. In particular, the phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be thermotolerant and/or thermostable. Also provided are methods for obtaining a variant polynucleotide encoding a phytase and for obtaining a phytase with thermostability or thermotolerant at high or low temperatures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2003:147728 USPATFULL
TITLE: Recombinant phytases and uses thereof
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
Mathur, Eric J., Carlsbad, CA, UNITED STATES
Richardson, Toby, San Diego, CA, UNITED STATES
Robertson, Dan, Solana Beach, CA, UNITED STATES
Barton, Nelson, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003101476	A1	20030529
APPLICATION INFO.:	US 2001-21723	A1	20011212 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255090P	20001212 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jane M. Love, Ph.D., Hale and Dorr LLP, 300 Park Avenue, New York, NY, 10022
NUMBER OF CLAIMS: 172
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 6576
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided is a new recombinant phytase enzyme. The enzyme can be produced from recombinant host cells and can be used to aid in the digestion of phytate where desired. In particular, the phytase of the present invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 27 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:71530 USPATFULL
TITLE: Recombinant bacterial phytases and uses thereof
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
PATENT ASSIGNEE(S): Diversa Corporation, San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049815	A1	20030313
APPLICATION INFO.:	US 2001-34985	A1	20011221 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-580515, filed on 25 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-318528, filed on 25 May 1999, GRANTED, Pat. No. US 6183740 Continuation-in-part of Ser. No. US 1999-291931, filed on 13 Apr 1999, GRANTED, Pat. No. US 6190897 Continuation-in-part of Ser. No. US 1999-259214, filed on 1 Mar 1999, GRANTED, Pat. No. US 6110719 Division of Ser. No. US 1997-910798, filed on 13 Aug 1997, GRANTED, Pat. No. US 5876997
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LISA A. HAILE, Ph.D., GRAY CARY WARE & FREIDENRICH LLP, 4365 Executive Drive, Suite 1100, San Diego, CA, 92121-2133
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 4714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A purified recombinant phytase enzyme derived from Escherichia coli B. The enzyme has a molecular weight of about 47.1 kilodaltons and has phytase activity. The enzyme can be produced from native or recombinant host cells and can be used to aid in the digestion of phytate where desired. In particular, the phytase of the present invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 28 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:70923 USPATFULL
TITLE: Over-coated chewing gum formulations
INVENTOR(S): Ream, Ronald L., Plano, IL, UNITED STATES
Greenberg, Michael J., Northbrook, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES
Corriveau, Christine L., Orland Park, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049208	A1	20030313
	US 6773716	B2	20040810
APPLICATION INFO.:	US 2001-992122	A1	20011113 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355265
Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1999-US29742	19991214

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Robert M. Barrett, Bell, Boyd & Lloyd LLC, P.O. Box 1135, Chicago, IL, 60690-1135
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1678
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a center comprising a gum base. By chewing the product, the medicament or agent is released from the product. Continuing to chew the product creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 29 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:3118 USPATFULL
TITLE: Over-coated product including tableted center and medicament
INVENTOR(S): Ream, Ronald L., Plano, IL, UNITED STATES
Matulewicz, Leonard, Oswego, IL, UNITED STATES
Wokas, William J., Bolingbrook, IL, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2003003152 A1 20030102
APPLICATION INFO.: US 2002-206492 A1 20020726 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2000-631326, filed on 3 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-618808, filed on 18 Jul 2000, GRANTED, Pat. No. US 6322806 Continuation-in-part of Ser. No. US 2000-510878, filed on 23 Feb 2000, GRANTED, Pat. No. US 6355265 Continuation-in-part of Ser. No. US 1999-286818, filed on 6 Apr 1999, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Bell, Boyd & Lloyd, LLC, P.O. Box 1135, Chicago, IL, 60690-1135
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1074
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted center. The tableted center is defined by compressible excipients. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l11 not py>2001
L12 13 L11 NOT PY>2001

=> d ibib abs tot

L12 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:466685 HCAPLUS
DOCUMENT NUMBER: 109:66685
TITLE: Suncus murinus as a new experimental model for motion sickness
AUTHOR(S): Ueno, Shinya; Matsuki, Norio; Saito, Hiroshi
CORPORATE SOURCE: Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan
SOURCE: Life Sciences (1988), 43(5), 413-20
CODEN: LIFSAK; ISSN: 0024-3205
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The characteristics of motion sickness and the effects of possible prophylactic drugs were studied in S. murinus (house musk shrew) as a potential exptl. model for motion sickness. Mild reciprocal shaking (amplitude: 10-40 mm; frequency: 0.5-3.0 Hz) induced vomiting in most S. murinus within 2 min. Adaptation was observed when the motion stimulus was repeated with an interval of 2-3 days. During the repetitive motion training, both the number of sensitive animals and the number of vomiting episodes decreased, and the time from the start of shaking to the 1st vomiting was extended. S.c. injection of scopolamine (100 mg/kg), chlorpromazine (8 mg/kg), promethazine (50 mg/kg), diphenhydramine (20 mg/kg), chlorphenamine (20 mg/kg) and methamphetamine (2 mg/kg) decreased the emetic effect of motion sickness, but pyrilamine (20 mg/kg), meclizine (20 mg/kg) and dimenhydrinate (32 mg/kg) were not effective or were very weak. These results indicate that S. murinus is sensitive to motion stimulus and that antiemetic drugs are effective as prophylaxis. S. murinus Is useful as a new exptl. animal model for motion sickness.

L12 ANSWER 2 OF 13 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1990:303605 BIOSIS
DOCUMENT NUMBER: PREV199039021786; BR39:21786
TITLE: EFFECTS OF VARIOUS TYPES OF ANTIHISTAMINES AND INHIBITORS OF HISTAMINE RELEASE ON MOTION-INDUCED EMESIS OF SUNCUS-MURINUS.
AUTHOR(S): KAJI T [Reprint author]; MATSUKI N; SAITO H
CORPORATE SOURCE: DEP CHEM PHARMACOL, FAC PHARMACEUTICAL SCI, UNIV TOKYO, TOKYO 113, JPN
SOURCE: Japanese Journal of Pharmacology, (1990) Vol. 52, No. SUPPL. 1, pp. 194P.
Meeting Info.: 63RD ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY, TOKYO, JAPAN, MARCH 25-28, 1990.
JPN J PHARMACOL.
CODEN: JJPAAZ. ISSN: 0021-5198.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 27 Jun 1990
Last Updated on STN: 7 Aug 1990

L12 ANSWER 3 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2000:12451 USPATFULL
TITLE: Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
INVENTOR(S): Parab, Prakash, Williamsville, NY, United States
Yu, Cheng Der Tony, Amherst, NY, United States
Patel, Bhiku, Amherst, NY, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6019988		20000201	
APPLICATION INFO.:	US 1996-751293		19961118	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Clardy, S. Mark
ASSISTANT EXAMINER: Shelborne, Kathryne E.
LEGAL REPRESENTATIVE: Simon, Morton S., Zeller, Charles J.
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and means for enhancing the epidermal, transdermal and dermal permeation of a topically applied pharmacologically active agent (e.g., a drug or medicament) which has a low rate of skin penetration in the absence of a permeation enhancer and which is unstable and degrades during long-term storage with particular permeation enhancers. Also provided by the invention are methods and means to increase the skin penetration of a pharmacologically active agent which has a normally low rate of skin permeation and causes the instability and degradation of a permeation enhancer with which it is combined over a long period of time. Provided by the invention are at least one first composition containing a drug, a pharmaceutically acceptable salt, chemical derivative or formulation thereof, in a dermatologically acceptable vehicle, and at least one second composition containing a permeation enhancer in an acceptable vehicle. The compositions are physically separated until application to a body or skin surface and are topically applied, either at the same time, or

sequentially within a short time of each other, and mixed or blended to form a final active composition, preferably on the skin. In addition, a premixture of the compositions can be made and applied to the skin in accordance with the invention. The invention allows a therapeutically effective amount of drug to be delivered into the skin and systemic circulation and provides significant enhancement of a drug's otherwise low level of skin permeation by the action of permeation enhancer in the active composition at the point of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 13 USPATFULL on STN

ACCESSION NUMBER:	1999:67030 USPATFULL
TITLE:	Prophylactic and therapeutic treatment of skin sensitization and irritation
INVENTOR(S):	Wille, John J., Trenton, NJ, United States Kydonieus, Agis, Kendall Park, NJ, United States
PATENT ASSIGNEE(S):	E.R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5912010		19990615
APPLICATION INFO.:	US 1997-897905		19970721 (8)

RELATED APPLN. INFO.:	Division of Ser. No. US 1995-545244, filed on 19 Oct 1995, now patented, Pat. No. US 5686100 which is a continuation-in-part of Ser. No. US 1994-343156, filed on 22 Nov 1994, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Brouillette, D. Gabrielle
LEGAL REPRESENTATIVE:	Kilcoyne, John M., Furman, Jr., Theodore R.
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
LINE COUNT:	906

AB Methods and devices for preventing and/or treating an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of a loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid.

L12 ANSWER 5 OF 13 USPATFULL on STN

ACCESSION NUMBER:	1998:150981 USPATFULL
TITLE:	Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
INVENTOR(S):	Wille, John J., Trenton, NJ, United States Kydonieus, Agis F., Kendall Park, NJ, United States
PATENT ASSIGNEE(S):	Bristol-Myers Squibb Company, Skillman, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843979		19981201
APPLICATION INFO.:	US 1996-598627		19960212 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-198003, filed on 17 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-22080, filed on 25 Feb 1993, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Fay, Zohreh
LEGAL REPRESENTATIVE:	Kilcoyne, John M., Furman, Jr., Theodore R.

NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1565
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for inhibiting or preventing the skin irritating or sensitizing effects of a skin irritating or sensitizing component of a dermal or transdermal drug delivery system are disclosed. The composition comprises a mast cell degranulating agent which is capable of inducing a state of immunological tolerance to the skin sensitizing agent by delivery prior to, or at the onset of transdermal drug delivery. Such an agent, preferably cis-urocanic acid or an analogue or metabolite thereof, can be administered before, during or after each transdermal drug delivery to achieve immune tolerance countersensitization. Alternatively, the agent can be used to induce countersensitization. The agent is preferably capable of permeating the epidermis and is administered transdermally. Novel methods and compositions comprising cis-urocanic acid or an analogue or metabolite thereof to obtain anti-inflammatory effects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 13 USPATFULL on STN
ACCESSION NUMBER: 1998:14834 USPATFULL
TITLE: Prophylactic and therapeutic treatment of skin sensitization and irritation
INVENTOR(S): Wille, John J., Trenton, NJ, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5716987		19980210	
APPLICATION INFO.:	US 1996-670201		19960621	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Furman, Jr., Theodore R., Kilcoyne, John M.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 674
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods, compositions and systems for preventing an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of phenoxyacetic acid and/or a lower alkyl ester thereof to a warm blooded animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 13 USPATFULL on STN
ACCESSION NUMBER: 97:104132 USPATFULL
TITLE: Prophylactic and therapeutic treatment of skin sensitization and irritation
INVENTOR(S): Wille, John J., Trenton, NJ, United States
Kydonieus, Agis, Kendall Park, NJ, United States
PATENT ASSIGNEE(S): E.R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5686100		19971111	
APPLICATION INFO.:	US 1995-545244		19951019	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-343156, filed			

on 22 Nov 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phelan, D. Gabrielle
LEGAL REPRESENTATIVE: Kilcoyne, John M., Furman, Jr., Theodore R.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 975
AB Methods and devices for preventing and/or treating an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of a loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid.

L12 ANSWER 8 OF 13 USPATFULL on STN
ACCESSION NUMBER: 97:29222 USPATFULL
TITLE: Prophylactic treatment of allergic contact dermatitis
INVENTOR(S): Wille, John J., Trenton, NJ, United States
Kydonieus, Agis, Kendall Park, NJ, United States
Castellana, Frank S., Princeton, NJ, United States
PATENT ASSIGNEE(S): E.R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5618557		19970408	
APPLICATION INFO.:	US 1994-343157		19941122	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phelan, D. Gabrielle
LEGAL REPRESENTATIVE: Furman, Jr., Theodore R., Kilcoyne, John M.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and devices for preventing an adverse reaction of the skin to the presence of a skin-sensitizing agent by administering an effective amount of a potassium-sparing diuretic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 13 USPATFULL on STN
ACCESSION NUMBER: 94:57611 USPATFULL
TITLE: Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
INVENTOR(S): Parab, Prakash V., Williamsville, NY, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5326566		19940705	
APPLICATION INFO.:	US 1993-108279		19930819	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-89069, filed on 7 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-790939, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-701944, filed on 17 May 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.

ASSISTANT EXAMINER: Bawa, Raj
LEGAL REPRESENTATIVE: Simon, Morton S.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to composition and methods for enhancing and/or controlling epidermal, dermal and transdermal penetration of topically applied pharmacologically active agents by use of dibutyl adipate, or a mixture of dibutyl adipate and isopropyl myristate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 13 USPATFULL on STN
ACCESSION NUMBER: 94:10707 USPATFULL
TITLE: Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
INVENTOR(S): Burns, James S., Darien, CT, United States
Marshak, Daniel R., Cold Spring Harbor, NY, United States
PATENT ASSIGNEE(S): Armstrong Pharmaceuticals, Inc., New Canaan, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5284133		19940208	
APPLICATION INFO.:	US 1992-919030		19920723	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Burr, Edgar S.
ASSISTANT EXAMINER: Asher, Kimberly L.
LEGAL REPRESENTATIVE: Whitham & Marhoefer
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 780
AB An inhalation device is provided with a mechanism to assure patient compliance with a drug dosage regimen. The control mechanism includes a controller (24), a timer (26), an actuator (28) and a signalling device (30). The controller (24) is programmed or preset with a time and dosage schedule for the drug to be delivered. For example, the controller (24) may be programmed to allow for two puffs from an MDI every eight hours. The actuator (28) operates in conjunction with the timer (26) and prevents the inhalation device from being actuated after the programmed dosage has been administered at the prescribed interval. The actuator (28) could be an electronically controlled valve (58) or pawl (66) arrangement or other suitable mechanism. The signaling device (30) provides an audible, visual or tactile sensation during the time period prescribed for administration of the drug so that the patient is reminded to inhale his or her medicine at the prescribed time intervals. The history of actuation, non-actuation, and improper attempts at actuation can all be recorded and analyzed off-site at a later by a physician, pharmacist, or other authorized health care professional.

L12 ANSWER 11 OF 13 USPATFULL on STN
ACCESSION NUMBER: 92:44652 USPATFULL
TITLE: Inducing skin tolerance to a sensitizing drug
INVENTOR(S): Amkraut, Alfred, Palo Alto, CA, United States
PATENT ASSIGNEE(S): ALZA Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5118509		19920602
APPLICATION INFO.:	US 1991-753271		19910830 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1989-364932, filed on 9 Jun 1989, now patented, Pat. No. US 5049387
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Horne, Leon R.
LEGAL REPRESENTATIVE: Miller, D. Byron, Mandell, Edward L., Stone, Steven F.
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 948

AB A method of inducing immune tolerance to a drug which is normally sensitizing to humans when applied to human skin or mucosa is provided. The sensitizing drug is continuously and co-extensively administered to a selected skin or mucosa site with the corticosteroid. Preferably, the corticosteroid is hydrocortisone or an ester thereof. The corticosteroid is administered to the selected skin or mucosa site at a rate and for a period of time sufficient to induce tolerance to the drug. Thereafter, the drug can be administered to the human, without administering any corticosteroid, without danger of inducing sensitization to the drug in the human.

L12 ANSWER 12 OF 13 USPATFULL on STN
ACCESSION NUMBER: 91:75534 USPATFULL
TITLE: Inducing skin tolerance to a sensitizing drug
INVENTOR(S): Amkraut, Alfred, Palo Alto, CA, United States
PATENT ASSIGNEE(S): Alza Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5049387		19910917
APPLICATION INFO.:	US 1989-364932		19890609 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1988-217014, filed on 8 Jul 1988, now patented, Pat. No. US 5000956
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Horne, Leon R.
LEGAL REPRESENTATIVE: Miller, D. Byron, Mandell, Edward L., Stone, Steven F.
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 941

AB A method of inducing immune tolerance to a drug which is normally sensitizing to humans when applied to human skin or mucosa is provided. The sensitizing drug is continuously and co-extensively administered to a selected skin or mucosa site with the corticosteroid. Preferably, the corticosteroid is hydrocortisone or an ester thereof. The corticosteroid is administered to the selected skin or mucosa site at a rate and for a period of time sufficient to induce tolerance to the drug. Thereafter, the drug can be administered to the human, without administering any corticosteroid, without danger of inducing sensitization to the drug in the human.

L12 ANSWER 13 OF 13 USPATFULL on STN
ACCESSION NUMBER: 89:1121 USPATFULL

TITLE: Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
INVENTOR(S): Kashdan, David S., Kingsport, TN, United States 37663
PATENT ASSIGNEE(S): Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4795641		19890103
APPLICATION INFO.:	US 1987-87566		19870820 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dixon, Jr., William R.
ASSISTANT EXAMINER: Brunsman, David M.
LEGAL REPRESENTATIVE: Savitsky, Thomas R., Heath, Jr., William P.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1081
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are polymer blends containing a minor amount of cellulose acetate and a major amount of cellulose acetate phthalate, cellulose acetate trimellitate or cellulose acetate succinate. The blends have reverse phase morphology, that is, the minor component forms a continuous phase. The blends are useful for zero-order controlled delivery of bioactive agents such as pharmaceutical and agricultural chemicals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	184.58	200.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

FILE 'STNGUIDE' ENTERED AT 20:10:43 ON 16 AUG 2006

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 11, 2006 (20060811/UP).

=>

---Logging off of STN---

Connection closed by remote host
END

Unable to generate the STN prompt.
Exiting the script...